

DAFTAR PUSTAKA

- Azuara-Blanco, A., Logan, N., Strang, N., Saunders, K., Allen, P. M., Weir, R., Doherty, P., Adams, C., Gardner, E., Hogg, R., McFarland, M., Preston, J., Verghis, R., Loughman, J. J., Flitcroft, I., Mackey, D. A., Lee, S. S.-Y., Hammond, C., Congdon, N., & Clarke, M. (2020). Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: A multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol. *The British Journal of Ophthalmology*, 104(7). <https://doi.org/10.1136/bjophthalmol-2019-314819>
- Berntsen, D. A., Sinnott, L. T., Mutti, D. O., & Zadnik, K. (2011). Accommodative lag and juvenile-onset myopia progression in children wearing refractive correction. *Vision Research*, 51(9), 1039–1046. <https://doi.org/10.1016/j.visres.2011.02.016>
- Berntsen, D. A., Sinnott, L. T., Mutti, D. O., & Zadnik, K. (2012). A Randomized Trial Using Progressive Addition Lenses to Evaluate Theories of Myopia Progression in Children with a High Lag of Accommodation. *Investigative Ophthalmology & Visual Science*, 53(2), 640. <https://doi.org/10.1167/iovs.11-7769>
- Bukhari, J., Li, S.-M., An, W.-Z., Du, J.-L., Liang, X.-T., Gan, J.-H., Tian, J.-X., Bai, W.-L., Cai, Z.-N., Yin, L., & Wang, N.-L. (2022). Effect of 0.01% atropine eyedrops on intraocular pressure in schoolchildren: A randomized clinical trial. *International Journal of Ophthalmology*, 15(9), 1431–1436. <https://doi.org/10.18240/ijo.2022.09.04>
- Carr, B. J. (2017, November 7). *The Science Behind Myopia*. Webvision: The Organization of the Retina and Visual System [Internet].
- Chakraborty, R., Read, S. A., & Vincent, S. J. (2020). Understanding Myopia: Pathogenesis and Mechanisms. In M. Ang & T. Y. Wong (Eds.), *Updates on Myopia* (pp. 65–94). Springer Singapore. https://doi.org/10.1007/978-981-13-8491-2_4
- Chaurasia, S., Negi, S., Kumar, A., Raj, S., Kaushik, S., Optom, R. K. M., Kishore, P., & Dogra, M. R. (2022). Efficacy of 0.01% low dose atropine and its correlation with various factors in myopia control in the Indian population. *Scientific Reports*, 12(1), 7113. <https://doi.org/10.1038/s41598-022-10079-1>
- Chen, C., & Yao, J. (2021). Efficacy and Adverse Effects of Atropine for Myopia Control in Children: A Meta-Analysis of Randomised Controlled Trials. *Journal of Ophthalmology*, 2021, 1–12. <https://doi.org/10.1155/2021/4274572>
- Cheng, D. (2010). Randomized Trial of Effect of Bifocal and Prismatic Bifocal Spectacles on Myopic Progression: Two-Year Results. *Archives of Ophthalmology*, 128(1), 12. <https://doi.org/10.1001/archophthalmol.2009.332>
- Cheng, D., Woo, G. C., Drobe, B., & Schmid, K. L. (2014). Effect of Bifocal and Prismatic Bifocal Spectacles on Myopia Progression in Children: Three-year Results of a Randomized Clinical Trial. *JAMA Ophthalmology*, 132(3), 358. <https://doi.org/10.1001/jamaophthalmol.2013.7623>
- Chua, W.-H., Cheung, Y.-B., Wong, W.-L., Lingham, A., Fong, A., & Tan, . (2012). Atropine for the Treatment of Childhood Myopia: Safety and



- Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). *Ophthalmology*, 119(2), 347–354. <https://doi.org/10.1016/j.ophtha.2011.07.031>
- Chia, A., Lu, Q.-S., & Tan, D. (2016). Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. *Ophthalmology*, 123(2), 391–399. <https://doi.org/10.1016/j.ophtha.2015.07.004>
- Clark, T. Y., & Clark, R. A. (2015). Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. *Journal of Ocular Pharmacology and Therapeutics*, 31(9), 541–545. <https://doi.org/10.1089/jop.2015.0043>
- Cui, C., Li, X., Lyu, Y., Wei, L., Zhao, B., Yu, S., Rong, J., Bai, Y., & Fu, A. (2021). Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: A 2-year clinical trial. *Scientific Reports*, 11(1), 22267. <https://doi.org/10.1038/s41598-021-01708-2>
- Drexler, W., Findl, O., Schmetterer, L., Hitzenberger, C. K., & Fercher, A. F. (1998). *Eye Elongation during Accommodation in Humans: Differences between Emmetropes and Myopes*. 39(11).
- Enthoven, C. A., Polling, J. R., Verzijden, T., Tideman, J. W. L., Al-Jaffar, N., Jansen, P. W., Raat, H., Metz, L., Verhoeven, V. J. M., & Klaver, C. C. W. (2021). Smartphone Use Associated with Refractive Error in Teenagers. *Ophthalmology*, 128(12), 1681–1688. <https://doi.org/10.1016/j.ophtha.2021.06.016>
- Flitcroft, D. I. (2014). Emmetropisation and the aetiology of refractive errors. *Eye*, 28(2), 169–179. <https://doi.org/10.1038/eye.2013.276>
- Flitcroft, D. I., He, M., Jonas, J. B., Jong, M., Naidoo, K., Ohno-Matsui, K., Rahi, J., Resnikoff, S., Vitale, S., & Yannuzzi, L. (2019). IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. *Investigative Ophthalmology & Visual Science*, 60(3), M20. <https://doi.org/10.1167/iovs.18-25957>
- Fu, A., Stapleton, F., Wei, L., Wang, W., Zhao, B., Watt, K., Ji, N., & Lyu, Y. (2020). Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: Low-dose atropine and myopia progression. *British Journal of Ophthalmology*, bjophthalmol-2019-315440. <https://doi.org/10.1136/bjophthalmol-2019-315440>
- Gallego, P., Martínez-García, C., Pérez-Merino, P., Ibares-Frías, L., Mayo-Iscar, A., & Merayo-Llodes, J. (2012). Scleral changes induced by atropine in chicks as an experimental model of myopia. *Ophthalmic and Physiological Optics*, 32(6), 478–484. <https://doi.org/10.1111/j.1475-1313.2012.00940.x>
- Gifford, K. L., Richdale, K., Kang, P., Aller, T. A., Lam, C. S., Liu, Y. M., Michaud, L., Mulder, J., Orr, J. B., Rose, K. A., Saunders, K. J., Seidel, D., Tideman, J. W. L., & Sankaridurg, P. (2019). IMI – Clinical Management Guidelines Report. *Investigative Ophthalmology & Visual Science*, 60(3), M184. <https://doi.org/10.1167/iovs.18-25977>
- Gwiazda, J., Hyman, L., Hussein, M., Everett, D., Norton, T. T., Kurtz, D., Leske, M. C., Manny, R., Marsh-Tootle, W., & Scheiman, M. (2003). A Randomized Clinical Trial of Progressive Addition Lenses versus Single Vision Lenses on the Progression of Myopia in Children. *Investigative ophthalmology & Visual Science*, 44(4), 1492. [tps://doi.org/10.1167/iovs.02-0816](https://doi.org/10.1167/iovs.02-0816)



- Gwiazda, J., Thorn, F., & Held, R. (1993). Myopic Children Show Insufficient Accommodative Response to Blur. *Investigative Ophthalmology & Visual Science*, 34.
- He, M., Xiang, F., Zeng, Y., Mai, J., Chen, Q., Zhang, J., Smith, W., Rose, K., & Morgan, I. G. (2015). Effect of Time Spent Outdoors at School on the Development of Myopia Among Children in China: A Randomized Clinical Trial. *JAMA*, 314(11), 1142. <https://doi.org/10.1001/jama.2015.10803>
- Hitzenberger, C. K., Drexler, W., Leitgeb, R. A., Findl, O., & Fercher, A. F. (2016). Key Developments for Partial Coherence Biometry and Optical Coherence Tomography in the Human Eye Made in Vienna. *Investigative Ophthalmology & Visual Science*, 57(9), OCT460. <https://doi.org/10.1167/iovs.16-19362>
- Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., Wong, T. Y., Naduvilath, T. J., & Resnikoff, S. (2016). Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. *Ophthalmology*, 123(5), 1036–1042. <https://doi.org/10.1016/j.ophtha.2016.01.006>
- Hvid-Hansen, A., Jacobsen, N., Hjortdal, J., Møller, F., Ozenne, B., & Kessel, L. (2023). Low-Dose Atropine Induces Changes in Ocular Biometrics in Myopic Children: Exploring Temporal Changes by Linear Mixed Models and Contribution to Treatment Effect by Mediation Analyses. *Journal of Clinical Medicine*, 12(4), 1605. <https://doi.org/10.3390/jcm12041605>
- Jiang, X., Tarczy-Hornoch, K., Cotter, S. A., Matsumura, S., Mitchell, P., Rose, K. A., Katz, J., Saw, S.-M., Varma, R., & for the POPEYE Consortium. (2020). Association of Parental Myopia With Higher Risk of Myopia Among Multiethnic Children Before School Age. *JAMA Ophthalmology*, 138(5), 501. <https://doi.org/10.1001/jamaophthalmol.2020.0412>
- Jinabhai, A. N., Feaoo, Mco. F. F., & Glover, M. (2019). How effective are atropine eye drops at reducing myopia progression in children? *Optometry in Practice*, 20(3), 18.
- Jonas, J. B., Ohno-Matsui, K., & Panda-Jonas, S. (2019). Myopia: Anatomic Changes and Consequences for Its Etiology. *Asia-Pacific Journal of Ophthalmology*, 8(5), 355–359. <https://doi.org/10.1097/01.APO.0000578944.25956.8b>
- Kaiti, R. (2022). Role of Atropine in the control of Myopia Progression- A Review. *Beyoglu Eye Journal*. <https://doi.org/10.14744/bej.2022.07742>
- Kaur, K., Gurnani, B., & Kannusamy, V. (2020). Myopia: Current concepts and review of literature. *TNOA Journal of Ophthalmic Science and Research*, 58(4), 280. https://doi.org/10.4103/tjosr.tjosr_85_20
- Kurtz, D., Hyman, L., Gwiazda, J. E., Manny, R., Dong, L. M., Wang, Y., & Scheiman, M. (2007). Role of Parental Myopia in the Progression of Myopia and Its Interaction with Treatment in COMET Children. *Investigative Ophthalmology & Visual Science*, 48(2), 562. <https://doi.org/10.1167/iovs.06-0408>
- Lam, C. S. Y., Tang, W. C., Tse, D. Y.-Y., Tang, Y. Y., & To, C. H. (2014). Defocus incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: A 2-year randomised clinical trial. *British Journal of Ophthalmology*, 98(1), 40–45. [tps://doi.org/10.1136/bjophthalmol-2013-303914](https://doi.org/10.1136/bjophthalmol-2013-303914)



- Lee, S. S., Lingham, G., Blaszkowska, M., Sanfilippo, P. G., Koay, A., Franchina, M., Chia, A., Loughman, J., Flitcroft, D. I., Hammond, C. J., Azuara-Blanco, A., Crewe, J. M., Clark, A., & Mackey, D. A. (2022). Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. *Clinical & Experimental Ophthalmology*, 50(9), 1001–1012. <https://doi.org/10.1111/ceo.14148>
- Li, F. F., Kam, K. W., Zhang, Y., Tang, S. M., Young, A. L., Chen, L. J., Tham, C. C., Pang, C. P., & Yam, J. C. (2020). Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine. *Ophthalmology*, 127(12), 1603–1611. <https://doi.org/10.1016/j.ophtha.2020.06.004>
- Li, H., Zhang, L., Tian, H., Zhang, S., Zhang, X., Zhang, H., Chen, Y., Qi, W., Wu, X., Jiang, H., Yang, H., Yang, Y., Liu, L., & Zhang, G. (2022). Effect of 0.01% Atropine on Accommodation in Myopic Teenagers. *Frontiers in Pharmacology*, 13, 808440. <https://doi.org/10.3389/fphar.2022.808440>
- Li, S.-M., Ji, Y.-Z., Wu, S.-S., Zhan, S.-Y., Wang, B., Liu, L.-R., Li, S.-Y., Wang, N.-L., & Wang, J. J. (2011). Multifocal Versus Single Vision Lenses Intervention to Slow Progression of Myopia in School-age Children: A Meta-analysis. *Survey of Ophthalmology*, 56(5), 451–460. <https://doi.org/10.1016/j.survophthal.2011.06.002>
- Liang, C., Jnawali, A., Curtin, S., & Vera-Diaz, F. A. (2022). Effect of Low Dose Atropine Eye Drops on Ocular Structure and Function. *Investigative Ophthalmology & Visual Science*, 63(7), 4315-A0020-4315-A0020.
- Lingham, G., Mackey, D. A., Lucas, R., & Yazar, S. (2020). How does spending time outdoors protect against myopia? A review. *British Journal of Ophthalmology*, 104(5), 593–599. <https://doi.org/10.1136/bjophthalmol-2019-314675>
- Luong, T. Q., Shu, Y.-H., Modjtahedi, B. S., Fong, D. S., Choudry, N., Tanaka, Y., & Nau, C. L. (2020). Racial and Ethnic Differences in Myopia Progression in a Large, Diverse Cohort of Pediatric Patients. *Investigative Ophthalmology & Visual Science*, 61(13), 20. <https://doi.org/10.1167/iovs.61.13.20>
- McCarthy, C. S., Megaw, P., Devadas, M., & Morgan, I. G. (2007). Dopaminergic agents affect the ability of brief periods of normal vision to prevent form-deprivation myopia. *Experimental Eye Research*, 84(1), 100–107. <https://doi.org/10.1016/j.exer.2006.09.018>
- Meng, W., Butterworth, J., Malecaze, F., & Calvas, P. (2011). Axial Length of Myopia: A Review of Current Research. *Ophthalmologica*, 225(3), 127–134. <https://doi.org/10.1159/000317072>
- Moriche-Carretero, M., Revilla-Amores, R., Gutiérrez-Blanco, A., Moreno-Morillo, F. J., Martínez-Pérez, C., Sánchez-Tena, M. Á., & Álvarez-Peregrina, C. (2024). Five-year results of atropine 0.01% efficacy in the myopia control in a European population. *The British Journal of Ophthalmology*, 108(5), 715–719. <https://doi.org/10.1136/bjo-2022-322808>
- Mutti, D. O., Mitchell, G. L., Jones, L. A., Friedman, N. E., Frane, S. L., Lin, W. K., Moeschberger, M. L., & Zadnik, K. (2005). Axial Growth and Changes in Lenticular and Corneal Power during Emmetropization in Infants. *Investigative Ophthalmology & Visual Science*, 46(9), 3074. <https://doi.org/10.1167/iovs.04-1040>
- O., Sinnott, L. T., Mitchell, G. L., Jones-Jordan, L. A., Moeschberger, M., Cotter, S. A., Kleinstei, R. N., Manny, R. E., Twelker, J. D., & Zadnik, K. (2011). Relative Peripheral Refractive Error and the Risk of Onset and



- Progression of Myopia in Children. *Investigative Ophthalmology & Visual Science*, 52(1), 199. <https://doi.org/10.1167/iovs.09-4826>
- Richter, G. M., Wang, M., Jiang, X., Wu, S., Wang, D., Torres, M., Choudhury, F., Varma, R., & for the Chinese American Eye Study Group. (2017). Ocular Determinants of Refractive Error and Its Age- and Sex-Related Variations in the Chinese American Eye Study. *JAMA Ophthalmology*, 135(7), 724. <https://doi.org/10.1001/jamaophthalmol.2017.1176>
- Rose, K. A., Morgan, I. G., Ip, J., Kifley, A., Huynh, S., Smith, W., & Mitchell, P. (2008). Outdoor Activity Reduces the Prevalence of Myopia in Children. *Ophthalmology*, 115(8), 1279–1285. <https://doi.org/10.1016/j.ophtha.2007.12.019>
- Sacchi, M., Serafino, M., Villani, E., Tagliabue, E., Luccarelli, S., Bonsignore, F., & Nucci, P. (2019). Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. *Acta Ophthalmologica*, 97(8). <https://doi.org/10.1111/aos.14166>
- Sankaridurg, P., Holden, B., Smith, E., Naduvilath, T., Chen, X., de la Jara, P. L., Martinez, A., Kwan, J., Ho, A., Frick, K., & Ge, J. (2011). Decrease in Rate of Myopia Progression with a Contact Lens Designed to Reduce Relative Peripheral Hyperopia: One-Year Results. *Investigative Ophthalmology & Visual Science*, 52(13), 9362. <https://doi.org/10.1167/iovs.11-7260>
- Saw, S. M. (2005). Eye growth changes in myopic children in Singapore. *British Journal of Ophthalmology*, 89(11), 1489–1494. <https://doi.org/10.1136/bjo.2005.071118>
- Saxena, R., Dhiman, R., Gupta, V., Kumar, P., Matalia, J., Roy, L., Swaminathan, M., Phuljhele, S., Velpandian, T., & Sharma, N. (2021). Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial. *Ophthalmology*, 128(9), 1367–1369. <https://doi.org/10.1016/j.ophtha.2021.01.026>
- Schwahn, H. N., Kaymak, H., & Schaeffel, F. (2000). Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. *Visual Neuroscience*, 17(2), 165–176. <https://doi.org/10.1017/S0952523800171184>
- Sen, S., Yadav, H., Jain, A., Verma, S., & Gupta, P. (2022). Effect of atropine 0.01% on progression of myopia. *Indian Journal of Ophthalmology*, 70(9), 3373. https://doi.org/10.4103/ijo.IJO_256_22
- Sherwin, J. C., & Mackey, D. A. (2013). Update on the epidemiology and genetics of myopic refractive error. *Expert Review of Ophthalmology*, 8(1), 63–87. <https://doi.org/10.1586/eop.12.81>
- Simonaviciute, D., Grzybowski, A., Gelzinis, A., & Zemaitiene, R. (2024). Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study. *Journal of Clinical Medicine*, 13(11), 3218. <https://doi.org/10.3390/jcm13113218>
- Smith, E. L., Ramamirtham, R., Qiao-Grider, Y., Hung, L.-F., Huang, J., Kee, C., Coats, D., & Paysse, E. (2007). Effects of Foveal Ablation on Emmetropization and Form-Deprivation Myopia. *Investigative Ophthalmology & Visual Science*, 48(9), 3914. <https://doi.org/10.1167/iovs.06-1264>
- A-J. Study Group, Hieda, O., Hiraoka, T., Fujikado, T., Ishiko, S., Hasebe, T., Torii, H., Takahashi, H., Nakamura, Y., Sotozono, C., Oshika, T., Shimoto, T., Nishida, K., Nishikawa, N., Song, Y.-S., Tokutake, T., Nishi,



- Y., Shigeno, Y., Kurihara, T., ... Kinoshita, S. (2021). Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. *Japanese Journal of Ophthalmology*, 65(3), 315–325. <https://doi.org/10.1007/s10384-021-00822-y>
- Torii, H., Ohnuma, K., Kurihara, T., Tsubota, K., & Negishi, K. (2017). Violet Light Transmission is Related to Myopia Progression in Adult High Myopia. *Scientific Reports*, 7(1), 14523. <https://doi.org/10.1038/s41598-017-09388-7>
- Tsai, H.-R., Chen, T.-L., Wang, J.-H., Huang, H.-K., & Chiu, C.-J. (2021). Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis. *Journal of Clinical Medicine*, 10(17), 3766. <https://doi.org/10.3390/jcm10173766>
- Upadhyay, A., & Beuerman, R. W. (2020). Biological Mechanisms of Atropine Control of Myopia. *Eye & Contact Lens: Science & Clinical Practice*, 46(3), 129–135. <https://doi.org/10.1097/ICL.0000000000000677>
- Walline, J. J. (2016). Myopia Control: A Review. *Eye & Contact Lens: Science & Clinical Practice*, 42(1), 3–8. <https://doi.org/10.1097/ICL.0000000000000207>
- Walline, J. J., Greiner, K. L., McVey, M. E., & Jones-Jordan, L. A. (2013). Multifocal Contact Lens Myopia Control. *Optometry and Vision Science*, 90(11), 1207–1214. <https://doi.org/10.1097/OPX.0000000000000036>
- Walline, J., & Smith, M. (2015). Controlling myopia progression in children and adolescents. *Adolescent Health, Medicine and Therapeutics*, 133. <https://doi.org/10.2147/AHMT.S55834>
- Wang, J., Li, Y., Musch, D. C., Wei, N., Qi, X., Ding, G., Li, X., Li, J., Song, L., Zhang, Y., Ning, Y., Zeng, X., Hua, N., Li, S., & Qian, X. (2021). Progression of Myopia in School-Aged Children After COVID-19 Home Confinement. *JAMA Ophthalmology*, 139(3), 293. <https://doi.org/10.1001/jamaophthalmol.2020.6239>
- Wang, Y., Zhu, X., Xuan, Y., Wang, M., Zhou, X., & Qu, X. (2022). Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children. *Ophthalmology and Therapy*, 11(2), 833–856. <https://doi.org/10.1007/s40123-022-00476-0>
- Wei, S., Li, S.-M., An, W., Du, J., Liang, X., Sun, Y., Gan, J., Bai, W., Tian, J., Cai, Z., Yin, L., & Wang, N. (2022). Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial. *Acta Ophthalmologica*. <https://doi.org/10.1111/aos.15235>
- Wei, S., Li, S.-M., An, W., Du, J., Liang, X., Sun, Y., Zhang, D., Tian, J., & Wang, N. (2020). Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial. *JAMA Ophthalmology*, 138(11), 1178. <https://doi.org/10.1001/jamaophthalmol.2020.3820>
- Wen, L., Cao, Y., Cheng, Q., Li, X., Pan, L., Li, L., Zhu, H., Lan, W., & Yang, Z. (2020). Objectively measured near work, outdoor exposure and myopia in children. *British Journal of Ophthalmology*, bjophthalmol-2019-315258. <https://doi.org/10.1136/bjophthalmol-2019-315258>
- World Health Organization. (2015). *Impact of increasing prevalence of myopia and high myopia: Report of Joint World Health Organization—Brien Holden Vision Institute Global Scientific Meeting on Myopia*. World Health



- Organization. https://myopiainstitute.org/wp-content/uploads/2020/10/Myopia_report_020517.pdf
- Wu, J., Gong, H., Li, H., Liang, J., Zhang, X., Yang, H., Liu, X., Zhang, G., Cheng, G., Bai, G., & Zhang, H. (2023). Changes in choroidal thickness in myopic children with 0.01% atropine: Evidence from a 12-month follow-up. *Photodiagnosis and Photodynamic Therapy*, 42, 103528. <https://doi.org/10.1016/j.pdpdt.2023.103528>
- Wu, P.-C., Chuang, M.-N., Choi, J., Chen, H., Wu, G., Ohno-Matsui, K., Jonas, J. B., & Cheung, C. M. G. (2019). Update in myopia and treatment strategy of atropine use in myopia control. *Eye*, 33(1), 3–13. <https://doi.org/10.1038/s41433-018-0139-7>
- Yam, J. C., Jiang, Y., & Lee, J. (2021). The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study. *American Journal of Ophthalmology*, 37, 146–153. <https://doi.org/10.1016/j.ajo.2021.12.005>
- Yam, J. C., Jiang, Y., Tang, S. M., Law, A. K. P., Chan, J. J., Wong, E., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2019). Low-Concentration Atropine for Myopia Progression (LAMP) Study. *Ophthalmology*, 126(1), 113–124. <https://doi.org/10.1016/j.ophtha.2018.05.029>
- Yam, J. C., Li, F. F., Zhang, X., Tang, S. M., Yip, B. H. K., Kam, K. W., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2020). Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study. *Ophthalmology*, 127(7), 910–919. <https://doi.org/10.1016/j.ophtha.2019.12.011>
- Ye, L., Xu, H., Shi, Y., Yin, Y., Yu, T., Peng, Y., Li, S., He, J., Zhu, J., & Xu, X. (2022). Efficacy and Safety of Consecutive Use of 1% and 0.01% Atropine for Myopia Control in Chinese Children: The Atropine for Children and Adolescent Myopia Progression Study. *Ophthalmology and Therapy*, 11(6), 2197–2210. <https://doi.org/10.1007/s40123-022-00572-1>
- Zadnik, K., Mutti, D. O., Mitchell, G. L., Jones, L. A., Burr, D., & Moeschberger, M. L. (2004). Normal Eye Growth in Emmetropic Schoolchildren: *Optometry and Vision Science*, 81(11), 819–828. <https://doi.org/10.1097/01.OPX.0000145028.53923.67>
- Zadnik, K., Satariano, W. A., Mutti, D. O., Sholtz, R. I., & Adams, J. (1994). The Effect of Parental History of Myopia on Children's Eye Size. *JAMA Ophthalmology*, 271(17).
- Zhao, C., Cai, C., Ding, Q., & Dai, H. (2020). Efficacy and safety of atropine to control myopia progression: A systematic review and meta-analysis. *BMC Ophthalmology*, 20(1), 1–8.
- Zhao, Q., & Hao, Q. (2021). Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children. *International Ophthalmology*, 41(3), 1011–1017. <https://doi.org/10.1007/s10792-020-01658-0>



LAMPIRAN 1



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, M.Med., Ph.D., Sp.GK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 370/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 9 Juni 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23050271		No Sponsor	
Peneliti Utama	dr. Ika Puspita		Sponsor	
Judul Peneliti	EFEK PEMBERIAN TETES MATA ATROPINE 0.01% SEBAGAI KONTROL MIOPIA PADA ANAK TERHADAP STATUS REFRAKSI DAN KOMPONEN BIOMETRIK OKULAR			
No Versi Protokol	2	Tanggal Versi	9 Juni 2023	
No Versi PSP	2	Tanggal Versi	9 Juni 2023	
Tempat Penelitian	RS Universitas Hasanuddin Dan Klinik Mata JEC Orbita Makassar			
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal 31 Mei 2023		Masa Berlaku 9 Juni 2023 sampai 9 Juni 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Optimized using
trial version
www.balesio.com

LAMPIRAN 2
FORMULIR PERSETUJUAN SAMPEL

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertanda tangan di bawah ini :

Nama :

Umur : tahun

Alamat :

Telepon/HP :

Menyatakan bersedia untuk berpartisipasi pada penelitian ini yang berjudul :

“EFEK PEMBERIAN TETES MATA ATROPINE 0.01% SEBAGAI KONTROL MIOPIA PADA ANAK TERHADAP STATUS REFRAKSI DAN KOMPONEN BIOMETRIK OKULAR”

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat yang akan didapatkan pada penelitian ini, khususnya bagi kemajuan ilmu kedokteran.

Makassar,

Responden/Wali

Saksi

(.....)

(.....)

Penanggung jawab penelitian :

dr. Ika Puspita
Citriland Tallasa City Blok C7 no.32
Telp. 0812 9271 1303

Penanggung jawab medik :

Dr. dr. Marlyanti Nur Rahmah Akib, Sp.M(K), M.Kes
ddopuli Raya Komp. Villa Surya Mas
0811 4441 610



LAMPIRAN 3. DATA INDUK PENELITIAN

No.	Kode	JK	Usia	Riwayat Orangtua	Riwayat Aktivitas Dekat	Riwayat Aktivitas Luar Ruangan	TIO (mmHg)			SE (D)			AL (mm)			K (D)			ACD (mm)			Ket.
							baseline	6 bulan	12 bulan	baseline	6 bulan	12 bulan	baseline	6 bulan	12 bulan	baseline	6 bulan	12 bulan	baseline	6 bulan	12 bulan	
1.	A01	P	9	salah satu	≥4 jam/hari	< 11 jam/mgg	11	10	11	-10,000	-10,375	-10,000	25,96	25,38	25,66	45,37	45,00	45,01	3,74	3,62	3,76	JEC
2.	A02	P	11	kedua orang tua	≥4 jam/hari	< 11 jam/mgg	15	16	13	-7,500	-7,370	-7,250	26,24	26,20	25,85	42,93	42,49	42,69	3,51	3,53	3,14	JEC
3.	A03	P	8	tidak ada	< 4 jam/hari	< 11 jam/mgg	11	10	12	-8,000	-8,000	-8,000	26,28	26,37	26,38	44,77	44,73	44,72	3,62	3,64	3,64	JEC
4.	A04	P	10	salah satu	≥4 jam/hari	< 11 jam/mgg	10	13	14	-7,250	-7,250	-7,750	26,14	26,00	26,48	42,64	42,13	42,26	3,45	3,25	3,47	RSUH
5.	A05	P	6	salah satu	≥4 jam/hari	< 11 jam/mgg	13	15	16	-10,000	-9,875	-9,875	25,60	25,77	25,75	44,22	44,34	44,28	3,62	3,60	3,64	JEC
6.	A06	L	6	tidak ada	≥4 jam/hari	≥11 jam/mgg	14	13	15	-8,250	-8,750	-8,750	25,73	25,96	25,85	42,19	43,75	43,62	3,34	3,31	3,36	JEC
7.	A07	L	7	tidak ada	≥4 jam/hari	≥11 jam/mgg	17	16	19	-6,000	-6,875	-6,875	24,49	24,63	24,60	45,18	45,33	45,36	3,41	3,60	3,57	RSUH
8.	A08	L	10	salah satu	≥4 jam/hari	< 11 jam/mgg	10	12	11	-8,500	-8,750	-9,000	26,56	26,65	26,69	42,80	42,56	43,34	3,44	3,62	3,65	RSUH
9.	A09	P	6	kedua orang tua	< 4 jam/hari	< 11 jam/mgg	11	12	12	-9,000	-9,000	-9,000	26,12	26,48	26,25	43,60	43,88	43,50	3,53	3,50	3,52	RSUH
10.	A10	P	7	tidak ada	≥4 jam/hari	≥11 jam/mgg	13	15	14	-9,750	-10,000	-10,000	24,76	23,95	24,69	46,00	46,25	46,38	4,86	4,73	4,82	RSUH
11.	A11	L	8	tidak ada	< 4 jam/hari	≥11 jam/mgg	12	10	11	-3,250	-3,125	-4,000	23,88	24,00	24,48	45,55	43,56	44,46	3,35	3,42	3,46	RSUH
12.	A12	L	6	salah satu	≥4 jam/hari	≥11 jam/mgg	12	11	11	-5,125	-5,625	-6,000	26,34	26,43	26,45	41,44	41,42	41,24	3,59	3,42	4,04	JEC
13.	A13	L	10	salah satu	< 4 jam/hari	≥11 jam/mgg	13	12	11	-4,375	-4,875	-4,875	26,56	25,58	25,64	42,65	43,01	43,12	3,86	3,72	3,98	RSUH
14.	A14	P	8	tidak ada	≥4 jam/hari	< 11 jam/mgg	13	18	16	-4,500	-4,500	-4,675	24,45	24,50	24,62	44,25	44,29	44,34	3,39	3,42	3,40	RSUH
15.	A15	L	12	tidak ada	≥4 jam/hari	≥11 jam/mgg	13	14	11	-5,000	-5,000	-5,000	25,19	25,20	25,32	43,89	43,88	43,82	3,84	3,79	3,67	RSUH
16.	A16	L	8	salah satu	< 4 jam/hari	< 11 jam/mgg	12	14	14	-3,250	-3,250	-3,500	25,26	25,02	25,16	42,70	42,51	42,58	3,08	3,12	3,13	RSUH
17.	A17	L	7	tidak ada	≥4 jam/hari	< 11 jam/mgg	12	12	13	-3,750	-3,250	-3,250	23,16	23,00	23,42	45,20	44,36	45,29	3,68	3,52	3,60	RSUH
18.	A18	L	11	salah satu	< 4 jam/hari	≥11 jam/mgg	17	15	16	-2,750	-2,750	-2,750	25,04	25,08	25,14	41,37	41,19	41,14	3,64	3,65	3,65	JEC
19.	A19	P	8	salah satu	≥4 jam/hari	< 11 jam/mgg	13	14	13	-1,750	-1,750	-2,000	23,57	23,08	23,50	43,34	43,00	43,14	3,49	3,50	3,53	RSUH
20.	A20	L	10	salah satu	≥4 jam/hari	≥11 jam/mgg	15	25	20	-1,750	-1,750	-1,750	25,32	25,28	25,42	41,60	41,55	41,67	3,99	3,95	3,96	RSUH
21.	A21	L	6	tidak ada	< 4 jam/hari	≥11 jam/mgg	10	10	11	-2,500	-2,500	-2,750	23,97	23,82	24,17	44,21	44,27	44,14	3,50	3,48	3,51	RSUH
22.	A22	L	8	salah satu	< 4 jam/hari	< 11 jam/mgg	9	11	11	-2,500	-2,750	-2,750	24,97	24,62	24,78	43,01	42,96	43,04	3,42	3,40	3,37	RSUH
23.	A23	L	10	salah satu	≥4 jam/hari	< 11 jam/mgg	10	12	12	-0,500	-0,500	-0,500	23,43	22,59	23,43	42,30	43,37	42,54	3,42	3,39	3,13	RSUH
24.	K01	L	6	kedua orangtua	≥4 jam/hari	≥11 jam/mgg	11	11	12	-7,000	-7,250	-7,750	25,52	25,58	26,12	44,89	44,92	45,01	3,34	3,50	3,52	RSUH
25.	K02	L	11	tidak ada	≥4 jam/hari	< 11 jam/mgg	11	14	15	-6,250	-6,750	-6,750	25,64	25,49	25,81	43,75	43,68	44,82	3,55	3,63	3,52	RSUH
26.	K03	L	8	kedua orangtua	≥4 jam/hari	≥11 jam/mgg	14	17	15	-7,125	-7,250	-7,500	25,88	25,98	26,01	42,85	42,73	42,75	3,42	3,00	3,33	JEC
27.	K04	L	9	tidak ada	< 4 jam/hari	< 11 jam/mgg	13	11	14	-8,000	-8,250	-8,250	25,63	25,65	25,7	45,17	45,20	45,38	3,58	3,52	3,47	RSUH
28.	K05	L	10	tidak ada	≥4 jam/hari	< 11 jam/mgg	12	13	15	-7,375	-7,750	-8,250	25,88	25,85	25,98	45,09	45,21	45,19	3,91	3,94	3,94	RSUH
29.	K06	L	11	tidak ada	≥4 jam/hari	< 11 jam/mgg	10	12	12	-8,000	-8,375	-8,675	26	25,64	25,62	44,76	44,78	44,73	3,64	3,77	3,66	RSUH



30.	K07	P	10	tidak ada	≥4 jam/hari	< 11 jam/mgg	12	11	14	-7,500	-7,750	-8,250	26,00	26.62	26.65	43,85	44,06	44,14	3,93	3,42	3,72	JEC
31.	K08	P	6	tidak ada	< 4 jam/hari	< 11 jam/mgg	12	11	11	-8,375	-8,375	-8,375	26,22	25.07	25.02	45,64	45,63	45,63	3,64	3,77	3,76	RSUH
32.	K09	P	6	tidak ada	< 4 jam/hari	< 11 jam/mgg	12	14	13	-8,375	-8,375	-8,377	25,09	25.11	25.19	45,48	45,52	45,59	3,56	3,65	3,69	RSUH
33.	K10	P	7	tidak ada	≥4 jam/hari	≥11 jam/mgg	16	14	17	-4,750	-4,375	-4,376	24,26	24.32	24.32	44,66	44,45	44,45	3,71	3,77	3,76	RSUH
34.	K11	P	7	salah satu	≥4 jam/hari	< 11 jam/mgg	12	13	13	-5,750	-5,750	-6,000	25,26	25.40	25.41	42,45	42,51	42,50	3,42	3,44	3,51	RSUH
35.	K12	L	9	salah satu	≥4 jam/hari	≥11 jam/mgg	12	12	13	-5,750	-6,000	-6,250	25,20	25.50	25.68	44,86	44,91	45,02	3,57	3,52	3,55	RSUH
36.	K13	P	10	salah satu	< 4 jam/hari	≥11 jam/mgg	16	14	17	-3,000	-3,250	-3,750	24,68	24.75	24.74	44,18	44,20	44,19	3,64	3,60	3,69	RSUH
37.	K14	P	10	salah satu	< 4 jam/hari	≥11 jam/mgg	16	15	13	-3,625	-3,750	-4,500	24,83	24.87	24.92	44,62	44,63	44,65	3,24	3,33	3,40	RSUH
38.	K15	P	7	tidak ada	≥4 jam/hari	< 11 jam/mgg	15	17	14	-3,375	-3,625	-3,875	23,19	23.4	23.52	45,77	45,78	45,77	3,51	3,56	3,59	JEC
39.	K16	P	8	salah satu	≥4 jam/hari	< 11 jam/mgg	12	14	13	-4,875	-5,125	-5,125	24,21	24.27	24.29	45,11	45,11	45,16	3,58	3,61	3,63	JEC
40.	K17	L	11	tidak ada	≥4 jam/hari	< 11 jam/mgg	12	11	13	-2,625	-3,125	-3,500	23,21	23.62	23.60	45,25	45,20	45,52	3,77	3,71	3,79	JEC
41.	K18	P	7	salah satu	< 4 jam/hari	≥11 jam/mgg	12	11	12	-2,000	-2,000	-2,250	22,45	22.68	22.46	46,25	46,45	46,47	3,46	3,50	3,69	RSUH
42.	K19	P	7	salah satu	< 4 jam/hari	≥11 jam/mgg	11	12	14	-2,000	-2,250	-2,350	22,38	22.62	22.6	46,13	46,45	46,44	3,46	3,48	3,73	RSUH
43.	K20	P	10	tidak ada	≥4 jam/hari	< 11 jam/mgg	16	11	13	-1,750	-2,000	-2,750	22,31	22,37	22,30	46,26	45,97	45,50	2,46	2,07	2,48	RSUH
44.	K21	P	10	tidak ada	≥4 jam/hari	< 11 jam/mgg	15	16	14	-2,250	-2,000	-2,500	22,53	22,49	22,43	45,77	45,74	45,73	2,46	2,28	2,75	RSUH
45.	K22	P	10	salah satu	< 4 jam/hari	< 11 jam/mgg	14	12	14	-2,625	-2,870	-3,000	23,42	23,50	23,49	45,39	45,46	45,41	3,44	3,41	3,39	RSUH
46.	K23	P	10	salah satu	< 4 jam/hari	< 11 jam/mgg	11	12	11	-2,625	-2,625	-3,250	23,37	23,37	23,39	45,52	45,48	45,55	3,42	3,43	3,42	RSUH



LAMPIRAN 4. STATISTIK PENELITIAN

Uji Normalitas

	Tests of Normality					
	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Usia	.183	46	.000	.916	46	.003
SER baseline	.124	46	.072	.939	46	.018
SER 6 mo	.149	46	.012	.938	46	.016
SER 12 mo	.112	46	.190	.943	46	.025
changes 6 month	.196	46	.000	.848	46	.000
changes 12 month	.128	46	.058	.976	46	.462
K value baseline	.131	46	.048	.940	46	.019
K value 6 mo	.085	46	.200*	.965	46	.174
K value 12 mo	.113	46	.181	.951	46	.051
changes 6 month	.198	46	.000	.757	46	.000
changes 12 month	.147	46	.015	.867	46	.000
AL baseline	.114	46	.170	.929	46	.008
AL 6 mo	.122	46	.085	.950	46	.048
AL 12 mo	.117	46	.124	.941	46	.020
changes 6 month	.254	46	.000	.847	46	.000
changes 12 month	.206	46	.000	.804	46	.000
ACD baseline	.205	46	.000	.815	46	.000
ACD 6 mo	.233	46	.000	.779	46	.000
ACD 12 mo	.154	46	.008	.883	46	.000
changes 6 month	.200	46	.000	.872	46	.000
changes 12 month	.148	46	.014	.947	46	.037

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Karakteristik

Report

Usia

Intervensi	Mean	N	Std. Deviation
Atrorine	8.35	23	1.849
	8.87	23	1.914
	8.61	46	1.879



Optimized using
trial version
www.balesio.com

Report

Intervensi		SER baseline	AL baseline
Atropine	Mean	-5.44565	25.17478
	N	23	23
	Std. Deviation	2.980244	1.056241
Control	Mean	-5.00000	24.48522
	N	23	23
	Std. Deviation	2.388716	1.344605
Total	Mean	-5.22283	24.83000
	N	46	46
	Std. Deviation	2.680033	1.245325

Report

Intervensi		K value baseline	ACD baseline
Atropine	Mean	43.53043	3.59870
	N	23	23
	Std. Deviation	1.377626	.338584
Control	Mean	44.94348	3.46565
	N	23	23
	Std. Deviation	.994190	.357260
Total	Mean	44.23696	3.53217
	N	46	46
	Std. Deviation	1.386120	.350669

Crosstab

		Intervensi		Total
		Atropine	Control	
jeniskelamin	laki-laki	Count	14	5
		% of Total	30.4%	10.9%
	perempuan	Count	9	18
		% of Total	19.6%	39.1%
Total	Count	23	23	46
	% of Total	50.0%	50.0%	100.0%



Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1- sided)
Pearson Chi-Square	7.263 ^a	1	.007		
Continuity Correction ^b	5.739	1	.017		
Likelihood Ratio	7.497	1	.006		
Fisher's Exact Test				.016	.008
Linear-by-Linear Association	7.105	1	.008		
N of Valid Cases	46				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.50.

b. Computed only for a 2x2 table

Crosstab

			Intervensi		
			Atropine	Control	Total
riwayat orang tua	tidak ada	Count	9	12	21
		% of Total	19.6%	26.1%	45.7%
	salah satu	Count	12	9	21
		% of Total	26.1%	19.6%	45.7%
	keduanya	Count	2	2	4
		% of Total	4.3%	4.3%	8.7%
Total		Count	23	23	46
		% of Total	50.0%	50.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	.857 ^a	2	.651
Likelihood Ratio	.860	2	.650
Linear-by-Linear Association	.470	1	.493
N of Valid Cases	46		

a. 2 cells (33.3%) have expected count less than 5. The minimum expected

count is .00.



Crosstab

			Intervensi		
			Atropine	Control	Total
Riwayat aktivitas dekat	>= 4 jam per hari	Count	15	14	29
		% of Total	32.6%	30.4%	63.0%
	< 4 jam per hari	Count	8	9	17
		% of Total	17.4%	19.6%	37.0%
Total		Count	23	23	46
		% of Total	50.0%	50.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.093 ^a	1	.760		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.093	1	.760		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	.091	1	.763		
N of Valid Cases	46				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.50.

b. Computed only for a 2x2 table

Crosstab

			Intervensi		
			Atropine	Control	Total
aktivitasoutdoor	>= 11 jam/ minggu	Count	10	8	18
		% of Total	21.7%	17.4%	39.1%
	< 11 jam/minggu	Count	13	15	28
		% of Total	28.3%	32.6%	60.9%
	Total	Count	23	23	46
		% of Total	50.0%	50.0%	100.0%



Chi-Square Tests					
	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2-sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.365 ^a	1	.546		
Continuity Correction ^b	.091	1	.763		
Likelihood Ratio	.366	1	.545		
Fisher's Exact Test				.763	.382
Linear-by-Linear Association	.357	1	.550		
N of Valid Cases	46				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.00.

b. Computed only for a 2x2 table

Derajat Miopia * Intervensi Crosstabulation

			Intervensi		
			Atropine	Control	Total
Derajat Miopia	Berat	Count	10	9	19
		% of Total	21.7%	19.6%	41.3%
	Sedang	Count	7	7	14
		% of Total	15.2%	15.2%	30.4%
	Ringan	Count	6	7	13
		% of Total	13.0%	15.2%	28.3%
Total		Count	23	23	46
		% of Total	50.0%	50.0%	100.0%

Chi-Square Tests			
	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	.130 ^a	2	.937
Likelihood Ratio	.130	2	.937
Linear-by-Linear Association	.125	1	.723
N of Valid Cases	46		

(.0%) have expected count less than 5. The minimum expected count is .50.



		Report					
Intervensi		SER baseline	changes 6 month	changes 12 month	AL baseline	changes 6 month	changes 12 month
Atropine	Mean	-5.44565	-.11391	-.21957	25.17478	-.14913	.03087
	N	23	23	23	23	23	23
	Std. Deviation	2.980244	.289470	.347471	1.056241	.363817	.292045
Control	Mean	-5.00000	-.16830	-.46339	24.48522	.01696	.10826
	N	23	23	23	23	23	23
	Std. Deviation	2.388716	.211772	.337383	1.344605	.374001	.345328
Total	Mean	-5.22283	-.14111	-.34148	24.83000	-.06609	.06957
	N	46	46	46	46	46	46
	Std. Deviation	2.680033	.252284	.360373	1.245325	.374359	.318636

Group Statistics

	Intervensi	N	Mean	Std. Deviation	Std. Error Mean
changes 12 month	Atropine	23	-.21957	.347471	.072453
	Control	23	-.46339	.337383	.070349

Test Statistics^a

	SER baseline	changes 6 month	AL baseline	changes 6 month	changes 12 month
Mann-Whitney U	237.500	202.500	182.500	186.500	244.500
Wilcoxon W	513.500	478.500	458.500	462.500	520.500
Z	-.594	-1.400	-1.802	-1.715	-.440
Asymp. Sig. (2-tailed)	.553	.161	.072	.086	.660

a. Grouping Variable: Intervensi



Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
changes 12 month	Equal variances assumed	.000	.995	2.414	44	.020	.243826	.100987	.040300	.447352
	Equal variances not assumed			2.414	43.962	.020	.243826	.100987	.040295	.447357

Report

Intervensi		K value baseline	changes 6 month	changes 12 month	ACD baseline	changes 6 month	changes 12 month
Atropine	Mean	43.53043	-.06000	.02043	3.59870	-.02565	.01000
	N	23	23	23	23	23	23
	Std. Deviation	1.377626	.650545	.451754	.338584	.098895	.160142
Control	Mean	44.94348	.01696	.08304	3.46565	-.03478	.05565
	N	23	23	23	23	23	23
	Std. Deviation	.994190	.130225	.304622	.357260	.178093	.120636
Total	Mean	44.23696	-.02152	.05174	3.53217	-.03022	.03283
	N	46	46	46	46	46	46
	Std. Deviation	1.386120	.465517	.382284	.350669	.142509	.142075



Test Statistics ^a						
	K value baseline	changes 6 month	changes 12 month	ACD baseline	changes 6 month	changes 12 month
Mann-Whitney U	116.000	219.500	208.500	251.000	221.000	203.000
Wilcoxon W	392.000	495.500	484.500	527.000	497.000	479.000
Z	-3.263	-.989	-1.231	-.297	-.957	-1.355
Asymp. Sig. (2-tailed)	.001	.323	.218	.767	.339	.175

a. Grouping Variable: Intervensi

		Report						
Derajat Miopia	Intervensi		SER baseline	changes 6 month	changes 12 month	AL baseline	changes 6 month	changes 12 month
Berat	Atropine	Mean	-8.42500	-.19950	-.22500	25.78800	-.04900	.03200
		N	10	10	10	10	10	10
		Std. Deviation	1.307298	.318987	.357460	.673825	.370719	.222401
	Control	Mean	-7.55556	-.23622	-.46411	25.76222	-.05222	.07111
		N	9	9	9	9	9	9
		Std. Deviation	.704647	.170355	.328022	.334170	.463917	.530105
	Total	Mean	-8.01316	-.21689	-.33826	25.77579	-.05053	.05053
		N	19	19	19	19	19	19



Sedang	Atropine	Std. Deviation	1.128770	.253238	.356028	.526142	.405428	.387334
		Mean	-4.17857	-.05357	-.29286	24.97714	-.15857	.03571
		N	7	7	7	7	7	7
	Control	Std. Deviation	.776803	.352500	.469200	1.243097	.385721	.471341
		Mean	-4.44643	-.10714	-.39300	24.51857	.12571	.17857
		N	7	7	7	7	7	7
	Total	Std. Deviation	1.124669	.233057	.410662	.714643	.097272	.163445
		Mean	-4.31250	-.08036	-.34293	24.74786	-.01643	.10714
		N	14	14	14	14	14	14
		Std. Deviation	.938941	.288427	.426781	1.002767	.307886	.346930
		Mean	-1.95833	-.04167	-.12500	24.38333	-.30500	.02333
		N	6	6	6	6	6	6
Ringan	Atropine	Std. Deviation	.827899	.102062	.136931	.823885	.327338	.139809
		Mean	-2.26786	-.14214	-.53286	22.81000	-.00286	.08571
		N	7	7	7	7	7	7
	Control	Std. Deviation	.363924	.243616	.306348	.498096	.441615	.165616
		Mean	-2.12500	-.09577	-.34462	23.53615	-.14231	.05692
		N	13	13	13	13	13	13
	Total	Std. Deviation	.614495	.191658	.315472	1.036014	.408333	.151349



Group Statistics						
Derajat Miopia		Intervensi	N	Mean	Std. Deviation	Std. Error Mean
Berat	changes 12 month	Atropine	10	-.22500	.357460	.113039
		Control	9	-.46411	.328022	.109341
Sedang	changes 12 month	Atropine	7	-.29286	.469200	.177341
		Control	7	-.39300	.410662	.155216
Ringan	changes 12 month	Atropine	6	-.12500	.136931	.055902
		Control	7	-.53286	.306348	.115788



			Independent Samples Test								
			Levene's Test for Equality of Variances		t-test for Equality of Means						
Derajat Miopia			F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
										Lower	Upper
Berat	changes 12 month	Equal variances assumed	.132	.721	1.513	17	.149	.239111	.158021	-.094284	.572506
		Equal variances not assumed			1.520	16.989	.147	.239111	.157268	-.092711	.570934
Sedan g	changes 12 month	Equal variances assumed	.158	.698	.425	12	.678	.100143	.235673	-.413344	.613630
		Equal variances not assumed			.425	11.793	.679	.100143	.235673	-.414345	.614631
Ringan	changes 12 month	Equal variances assumed	6.816	.024	3.000	11	.012	.407857	.135951	.108632	.707083
		Equal variances not assumed			3.172	8.565	.012	.407857	.128577	.114727	.700987



		Test Statistics ^a				
Derajat Miopia		SER baseline	changes 6 month	AL baseline	changes 6 month	changes 12 month
Berat	Mann-Whitney U	24.500	35.000	35.000	38.000	41.000
	Wilcoxon W	79.500	80.000	80.000	83.000	96.000
	Z	-1.679	-.829	-.817	-.572	-.328
	Asymp. Sig. (2-tailed)	.093	.407	.414	.567	.743
	Exact Sig. [2*(1-tailed Sig.)]	.095 ^b	.447 ^b	.447 ^b	.604 ^b	.780 ^b
Sedang	Mann-Whitney U	21.000	19.500	19.500	9.000	24.000
	Wilcoxon W	49.000	47.500	47.500	37.000	52.000
	Z	-.448	-.654	-.640	-1.983	-.064
	Asymp. Sig. (2-tailed)	.654	.513	.522	.047	.949
	Exact Sig. [2*(1-tailed Sig.)]	.710 ^b	.535 ^b	.535 ^b	.053 ^b	1.000 ^b
Ringan	Mann-Whitney U	16.000	15.000	.000	8.500	18.000
	Wilcoxon W	44.000	43.000	28.000	29.500	39.000
	Z	-.724	-.938	-3.000	-1.788	-.429
	Asymp. Sig. (2-tailed)	.469	.348	.003	.074	.668
	Exact Sig. [2*(1-tailed Sig.)]	.534 ^b	.445 ^b	.001 ^b	.073 ^b	.731 ^b

a. Grouping Variable: Intervensi

b. Not corrected for ties.

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	11.469 ^a	4	.022
Likelihood Ratio	13.281	4	.010
Linear-by-Linear Association	.047	1	.828
N of Valid Cases	46		

(33.3%) have expected count less than 5. The minimum expected count is .13.



Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	2.524 ^a	2	.283
Likelihood Ratio	2.508	2	.285
Linear-by-Linear Association	2.392	1	.122
N of Valid Cases	46		

a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.80.

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	3.219 ^a	2	.200
Likelihood Ratio	3.233	2	.199
Linear-by-Linear Association	.725	1	.394
N of Valid Cases	46		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.09.

Ranks

Intervensi			N	Mean Rank	Sum of Ranks
Atropine	SER 6 mo - SER baseline	Negative Ranks	8 ^a	7.88	63.00
		Positive Ranks	4 ^b	3.75	15.00
		Ties	11 ^c		
		Total	23		
Control	SER 6 mo - SER baseline	Negative Ranks	17 ^a	9.68	164.50
		Positive Ranks	2 ^b	12.75	25.50
		Ties	4 ^c		
		Total	23		



mo < SER baseline
mo > SER baseline
mo = SER baseline

Test Statistics^a

Intervensi		SER 6 mo - SER baseline
Atropine	Z	-1.889 ^b
	Asymp. Sig. (2-tailed)	.059
Control	Z	-2.847 ^b
	Asymp. Sig. (2-tailed)	.004

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Ranks

Intervensi			N	Mean Rank	Sum of Ranks
Atropine	SER 12 mo - SER baseline	Negative Ranks	14 ^a	10.57	148.00
		Positive Ranks	4 ^b	5.75	23.00
		Ties	5 ^c		
		Total	23		
Control	SER 12 mo - SER baseline	Negative Ranks	20 ^a	11.80	236.00
		Positive Ranks	2 ^b	8.50	17.00
		Ties	1 ^c		
		Total	23		

a. SER 12 mo < SER baseline

b. SER 12 mo > SER baseline

c. SER 12 mo = SER baseline

Test Statistics^a

Intervensi		SER 12 mo - SER baseline
Atropine	Z	-2.740 ^b
	Asymp. Sig. (2-tailed)	.006
Control	Z	-3.570 ^b
	Asymp. Sig. (2-tailed)	.000



on Signed Ranks Test

on positive ranks.

Ranks

Intervensi			N	Mean Rank	Sum of Ranks
Atropine	AL 6 mo - AL baseline	Negative Ranks	11 ^a	14.23	156.50
		Positive Ranks	12 ^b	9.96	119.50
		Ties	0 ^c		
		Total	23		
	AL 12 mo - AL baseline	Negative Ranks	7 ^d	11.79	82.50
		Positive Ranks	15 ^e	11.37	170.50
		Ties	1 ^f		
		Total	23		
Control	AL 6 mo - AL baseline	Negative Ranks	5 ^a	13.70	68.50
		Positive Ranks	17 ^b	10.85	184.50
		Ties	1 ^c		
		Total	23		
	AL 12 mo - AL baseline	Negative Ranks	4 ^d	13.38	53.50
		Positive Ranks	19 ^e	11.71	222.50
		Ties	0 ^f		
		Total	23		

- a. AL 6 mo < AL baseline
- b. AL 6 mo > AL baseline
- c. AL 6 mo = AL baseline
- d. AL 12 mo < AL baseline
- e. AL 12 mo > AL baseline
- f. AL 12 mo = AL baseline

Test Statistics^a

Intervensi		K value 6 mo - K value baseline	K value 12 mo - K value baseline
Atropine	Z	-.745 ^b	-.183 ^b
	Asymp. Sig. (2-tailed)	.456	.855
Control	Z	-.812 ^c	-2.144 ^c
	Asymp. Sig. (2-tailed)	.417	.032



on Signed Ranks Test
on positive ranks.
on negative ranks.

Ranks					
Intervensi			N	Mean Rank	Sum of Ranks
Atropine	ACD 6 mo - ACD baseline	Negative Ranks	14 ^a	13.07	183.00
		Positive Ranks	9 ^b	10.33	93.00
		Ties	0 ^c		
		Total	23		
	ACD 12 mo - ACD baseline	Negative Ranks	8 ^d	14.31	114.50
		Positive Ranks	15 ^e	10.77	161.50
		Ties	0 ^f		
		Total	23		
Control	ACD 6 mo - ACD baseline	Negative Ranks	9 ^a	14.67	132.00
		Positive Ranks	14 ^b	10.29	144.00
		Ties	0 ^c		
		Total	23		
	ACD 12 mo - ACD baseline	Negative Ranks	6 ^d	10.33	62.00
		Positive Ranks	16 ^e	11.94	191.00
		Ties	1 ^f		
		Total	23		

- a. ACD 6 mo < ACD baseline
b. ACD 6 mo > ACD baseline
c. ACD 6 mo = ACD baseline
d. ACD 12 mo < ACD baseline
e. ACD 12 mo > ACD baseline
f. ACD 12 mo = ACD baseline

Test Statistics ^a		ACD 6 mo - ACD baseline	ACD 12 mo - ACD baseline
Intervensi			
Atropine	Z	-1.371 ^b	-.716 ^c
	Asymp. Sig. (2-tailed)	.170	.474
Control	Z	-.183 ^c	-2.097 ^c
	Asymp. Sig. (2-tailed)	.855	.036



on Signed Ranks Test
on positive ranks.
on negative ranks.